The Rise and Resilience of BioNTech: Navigating Post-Pandemic Challenges
BioNTech's 2024 Q4 earnings per share (EPS) reached €1.08, surpassing forecasts but down from €1.90 the previous year. Revenue decreased from €1.479 billion to €1.19 billion, though exceeded expectations of…